-+ 0.00%
-+ 0.00%
-+ 0.00%

DiaMedica Therapeutics Doses First Patients In Its Phase 2 Trial Of DM199 For The Treatment Of Fetal Growth Restriction

Benzinga·06/23/2026 12:34:03
Listen to the news
  • First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment
  • DM199 is intended to improve maternal uterine artery blood flow to the placenta without crossing into fetal circulation
  • Fetal Growth Restriction white paper authored by leading maternal-fetal medicine experts released